Please fill out this information for you and the healthcare professionals involved in relation to Tuberculosis (TB) testing. **Tuberculosis (TB) Tests and Treatment** (Check with your doctor if you do not know) Mark this box if you have ever had any test that was positive for TB Yes Mark this box if you have ever taken any medicines to treat or prevent TB: Yes Please record the date and results of your last screening for TB below: **Tuberculin test: Chest X-ray:** Please read the Yuflyma package leaflet for more If you have any other questions, talk to your HCP.

Your doctor's name (who prescribed Yuflyma):

Your doctor's phone no.:

Condition treated:

Date of your first Yuflyma injection:

Dose of your Yuflyma injection:

Date of your last Yuflyma injection (if no longer taking

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes

any possible side effects not listed in the Package Leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.

Please report side effects to: Mint Health Ltd, 3/4 Cantrija Complex, Triq it-Targa, Il-Maghtab, Naxxar NXR6613 Malta Tel: +356 2093 9800

Email: pharmacovigilancemt@mint.com.mt

Or report to: ADR Reporting

Sir Temi Zammit Buildings, Malta Life Sciences Park, San Gwann SGN 3000, Malta

Email: postlicensing.medicinesauthority@gov.mt Website: https://medicinesauthority.gov.mt/ adversedrugreactions?l=1

Patient reminder card may be downloaded from: https://medicinesauthority.gov.mt/rmm

OO HEALTHCARE
• CELLTRION

Celltrion Healthcare Hungary Kft.

1062 Budapest

Váci út 1-3. WestEnd Office Building B torony, Hungary
Date of Preparation: August 2025

Yuflyma[▼] (adalimumab)

Adult Patient Reminder Card

This card contains selected important safety information that you need to know before and during your treatment with Yuflyma.

- Keep this card with you at all times and for up to 4 months after your last injection of Yuflyma.
- Present this card to any doctor or healthcare professional that you see.
- You can record any tuberculosis tests or treatment you may have had, inside of this card.

If you have any questions, speak to your healthcare professional about your treatment.

Not all possible side effects are listed on the inside of this Card. Please read the Yuflyma package leaflet or speak with your HCP for more information about side effects.

Date of approval by Malta Medicines Authority: 08/08/2025

Fold Fold Fold

Introduction

abbreviation HCP: Health Care Professiona

Yuflyma is a medicine that is intended to treat certain diseases that affect the immune system.

While Yuflyma can be effective in treating these diseases, some people can have one or more side effects. It is important to talk to your HCP about the possible benefits and possible side effects of taking Yuflyma. These can be different for each person.

- The purpose of this card is to tell you about some of the possible side effects of Yuflyma.
- Some of the serious side effects that could occur include infections, cancer, and nervous system problems.
- This is not a full list of the possible side effects of Yuflyma.
- Certain vaccines may cause infections and should not be given while receiving Yuflyma. Please check with your doctor before you receive any vaccines.

Before Yuflyma Treatment

Tell your HCP about any health problems you have and any medicines you take. This will help the doctor decide if Yuflyma is right for you.
Tell your HCP if you:

- Have an infection or symptoms of an infection.
- Have tuberculosis or have been in close contact with someone with tuberculosis.
- Have or have had cancer.
- Have any numbness or tingling or have a problem that affects the nervous system.

Your HCP should check you for signs and symptoms of tuberculosis before starting Yuflyma. Before starting Yuflyma treatment, your HCP will test you for tuberculosis. Please inform them if you have a known history of tuberculosis.

Vaccination

- You can be vaccinated except for live vaccines.
- If you receive Yuflyma while you are pregnant, it is important that you inform your obstetrician before your baby receives any vaccine.
- Your baby should not receive a 'live vaccine', such as BCG (used to prevent tuberculosis) within 5 months following your last Yufyma injection during

During Yuflyma Treatment

To make sure that Yuflyma is working properly and safely for you, you should check in with your HCP regularly to discuss how you are doing. Tell the HCP right away about any changes in your condition.

Keep your HCP informed about how Yuflyma is working for you.

 It is important to call your HCP right away about any unusual symptoms you may have. This will help make sure you get the right care. It will also lower the chance of a side effect becoming worse. Many side effects including infections can be managed if you tell HCP right away.

- If you get a side effect, your HCP will decide if you should continue or stop Yuflyma treatment. It is important to talk with your HCP to find out what is right for you.
- Since side effects can happen after your last dose of Yuflyma, tell your HCP. about any problems that you may have up to 4 months after your last injection of Yuflyma.

Tell your HCP about:

- Any new medical conditions that you have.
- New medicines you are taking.
- Any surgery or operation that is planned for you.

Some people taking Yuflyma may get serious side effects, including:

Infections: Yuflyma helps people with certain inflammatory diseases. It does this by blocking a part of the immune system. However, this part of the immune system also helps fight infection. This means Yuflyma can make you more likely to get infections or make any infection that you may have worse. This includes infections such as colds or more serious infections like tuberculosis.

Cancer: If you take Yuflyma, the risk of getting lymphoma (a cancer that affects the lymph system), leukaemia (a cancer that affects the blood and bone marrow) or other cancers may increase. Cases of non-melanoma skin cancer have been observed in patients taking Yuflyma.

Nervous system problems: Some people have developed new or worsening nervous system problems with adalimumab. This includes multiple sclerosis.

Please read the Yuflyma package leaflet for more information. These are not all of the possible side effects that may occur during treatment with Yuflyma.

Call your HCP or get medical care right away if you have any of the following symptoms of these possible serious side effects:

Infections: fever, chills, unusual sweating, feeling unwell or more tired than normal, feeling or being sick (such as nausea or vomiting), diarrhoea, stomach pain, loss of appetite or weight loss, cough or coughing up blood or mucus, shortness of breath, problems urinating, skin sores, wounds, muscle aches, dental problems.

Cancer: night sweats; swelling of the lymph nodes (swollen glands) in the neck, armpits, groin or other areas; weight loss; new skin lesions or change in skin lesions (such as moles or freckles) you already have; severe itchiness that cannot be explained.

Nervous system problems: numbness or tingling, vision changes, muscles weakness, unexpected

Tell your HCP about any unusual symptoms that you have during treatment with Yuflyma. This includes any possible side-effects not listed in this leaflet.

110mm